Literature DB >> 28802758

Impact of rapid identification of Staphylococcus aureus bloodstream infection without antimicrobial stewardship intervention on antibiotic optimization and clinical outcomes.

R Brigg Turner1, Karineh Lalikian2, Madeline Fry2, Jacqueline Schwartz2, Dominic Chan3, Regina Won4.   

Abstract

Few studies have evaluated the clinical impact of polymerase chain reaction (PCR) for Staphylococcus aureus bloodstream infections in resource-limited settings that lack direct antimicrobial stewardship intervention. This retrospective cohort study compared patients with standard microbiological identification (n=343) to those with additional identification by (PCR) (n=130). Time to initiation of optimal therapy was similar between groups but substantially shorter in the PCR group for those infected with methicillin susceptible S. aureus (median 40.0h vs. 28.3h, P=0.001). After controlling for confounding factors including infectious diseases consultation, the PCR group had a shorter time to initiation of optimal therapy by 9.7h (95% CI 4.3-15.0h). Clinical outcomes were similar in the non-PCR and PCR groups. While time to initiation of optimal therapy was shorter in the PCR group, greater reductions may be realized through additional education, direct antimicrobial stewardship intervention, or additional clinician notification.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimicrobial stewardship; Bloodstream infection; Rapid diagnostics

Mesh:

Substances:

Year:  2017        PMID: 28802758     DOI: 10.1016/j.diagmicrobio.2017.07.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  1 in total

1.  Implementation of Rapid Diagnostic Testing without Active Stewardship Team Notification for Gram-Positive Blood Cultures in a Community Teaching Hospital.

Authors:  Paige M Bukowski; Joshua S Jacoby; Andrew P Jameson; Lisa E Dumkow
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.